poisar

Stocks · News reference

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

Vandana Singh

The FDA has warned Evolus that an Instagram post for Jeuveau is false or misleading and misbrands the drug.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

EOLS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    UTMD Trades at a Premium to the Industry: How to Play the Stock?

    Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.

    UTMDEOLSCGC